Korea National Enterprise for Clinical Trials (KoNECT) and the DIA  have signed a Memorandum of Understanding to establish a cooperative relationship and explore collaboration in development of training, education and knowledge exchange opportunities.  Both organizations have an interest in delivering educational offerings through classroom and on-line training courses along with additional opportunities to further develop and advance innovations in therapeutic product development.

KoNECT was established in April, 2014 as a non-profit foundation by the Korean Ministry of Health and Welfare for the purpose of furthering development of clinical trial infrastructure and capability, with an objective to establish Korea as a global clinical trial hub and preferred partner for drug development in the Asia Pacific region, as the continuum of the 1st KoNECT established in December 2007.

News

Korea National Enterprise for Clinical Trials (KoNECT) and DIA (Drug Information Association) have signed a Memorandum of Understanding to establish a cooperative relationship and explore collaboration in development of training, education and knowledge exchange opportunities.